Acttr3bp6: A Cancer-Related RNA Polymerase II Regulator (G644773)

Target Name: ACTR3BP6

NCBI ID: G644773

ACTR3BP6

Other Name(s): ACTR3B pseudogene 6

Acttr3bp6: A Cancer-Related RNA Polymerase II Regulator

ACTR3BP6, also known as ACTR3BP6 gene, is a gene located on chromosome 16p36.3 in humans. It encodes for the protein ACTR3BP6, which is a key regulator of the RNA polymerase II (RPNII) complex, a critical component of the transcription machinery that plays a vital role in gene expression. The regulation of RPNII complex by ACTR3BP6 is disrupted in a variety of genetic and computational models of cancer, leading to the potential for it to be a drug target or biomarker.

Diseases and Therapeutics

ACTR3BP6 has been implicated in several diseases, including cancer. In cancer, ACTR3BP6 has been shown to play a negative role in the regulation of RPNII complex, leading to the potential for it to be a drug target. Several studies have shown that inhibition of ACTR3BP6 has led to increased levels of RPNII complex, which can lead to increased gene expression and the expression of genes involved in cell growth, invasion, and metastasis.

One of the most promising strategies for targeting ACTR3BP6 is to inhibit its activity with small molecules, such as drugs that target RNA polymerase II (RPNII) complex. Several studies have shown that inhibitors of RPNII can significantly reduce the levels of ACTR3BP6 in cancer cells, leading to the potential for these drugs to be effective in cancer treatment.

Another approach to targeting ACTR3BP6 is to use genetic approaches to modify the expression of genes involved in the regulation of RPNII complex. This can include CRISPR/Cas9 genome editing to introduce mutations in the ACTR3BP6 gene that result in the production of a protein with altered activity. These mutations can then be used to create a library of potential drug targets by introducing them into cancer cells.

Methodology

To determine the effects of ACTR3BP6 on RPNII complex, several studies have used a variety of techniques to measure the levels of the protein in cancer cells. These studies have shown that ACTR3BP6 levels are elevated in cancer cells, and that inhibition of RPNII complex with small molecules or genetic approaches can significantly reduce these levels.

Additionally, several studies have used RNA sequencing (RNA-seq) to measure gene expression levels in cancer cells and to identify genes involved in the regulation of RPNII complex. These studies have shown that genes involved in the regulation of RPNII complex are highly expressed in cancer cells, and that inhibition of RPNII complex with small molecules or genetic approaches can significantly reduce the levels of these genes.

Conclusion

In conclusion, ACTR3BP6 is a gene that has been implicated in a variety of diseases, including cancer. Its regulation of the RNA polymerase II (RPNII) complex is a key factor in this regulation, and inhibition of RPNII complex with small molecules or genetic approaches is a promising strategy for targeting this protein and potentially treating cancer. Further research is needed to fully understand the role of ACTR3BP6 in cancer and to develop effective treatments.

Protein Name: ACTR3B Pseudogene 6

The "ACTR3BP6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACTR3BP6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets